Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Consensus Rating of “Moderate Buy” by Brokerages

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) has earned a consensus rating of “Moderate Buy” from the nine research firms that are presently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a hold recommendation and eight have assigned a buy recommendation to the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $23.3333.

ZVRA has been the subject of a number of recent research reports. Wall Street Zen upgraded shares of Zevra Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, April 11th. Guggenheim increased their price target on shares of Zevra Therapeutics from $23.00 to $25.00 and gave the company a “buy” rating in a research report on Friday, May 8th. Weiss Ratings upgraded shares of Zevra Therapeutics from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Friday, May 8th. Finally, BTIG Research started coverage on shares of Zevra Therapeutics in a research report on Monday, March 16th. They set a “buy” rating and a $23.00 price target for the company.

Zevra Therapeutics Price Performance

Zevra Therapeutics stock opened at $11.01 on Monday. The company has a market capitalization of $650.86 million, a PE ratio of 5.53 and a beta of 0.88. The firm’s fifty day moving average is $9.98 and its 200 day moving average is $9.26. Zevra Therapeutics has a 12-month low of $7.16 and a 12-month high of $13.16.

Zevra Therapeutics (NASDAQ:ZVRA) last announced its quarterly earnings results on Wednesday, May 6th. The company reported $0.18 EPS for the quarter, beating analysts’ consensus estimates of $0.06 by $0.12. The business had revenue of $36.22 million during the quarter, compared to analyst estimates of $31.96 million. Zevra Therapeutics had a net margin of 101.58% and a return on equity of 51.49%. Sell-side analysts expect that Zevra Therapeutics will post 0.56 EPS for the current fiscal year.

Hedge Funds Weigh In On Zevra Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. ProShare Advisors LLC boosted its position in Zevra Therapeutics by 12.3% during the fourth quarter. ProShare Advisors LLC now owns 12,669 shares of the company’s stock worth $114,000 after purchasing an additional 1,390 shares during the period. The Manufacturers Life Insurance Company boosted its position in Zevra Therapeutics by 9.4% during the second quarter. The Manufacturers Life Insurance Company now owns 20,294 shares of the company’s stock worth $179,000 after purchasing an additional 1,750 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in Zevra Therapeutics by 6.1% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 31,761 shares of the company’s stock worth $238,000 after purchasing an additional 1,812 shares during the period. Deutsche Bank AG boosted its position in Zevra Therapeutics by 4.4% during the fourth quarter. Deutsche Bank AG now owns 45,939 shares of the company’s stock worth $412,000 after purchasing an additional 1,936 shares during the period. Finally, CWM LLC boosted its position in Zevra Therapeutics by 399.5% during the third quarter. CWM LLC now owns 2,872 shares of the company’s stock worth $27,000 after purchasing an additional 2,297 shares during the period. Institutional investors own 35.03% of the company’s stock.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.